NASDAQ:CDLXCardlytics Stock Price, Forecast & News

Cardlytics' stock was trading at $45.83 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CDLX shares have increased by 68.0% and is now trading at $77.01. View which stocks have been most impacted by Coronavirus.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cardlytics in the last year. There are currently 1 sell rating, 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Cardlytics.

Cardlytics is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Cardlytics.

Cardlytics Inc (NASDAQ:CDLX) announced its earnings results on Monday, May, 11th. The company reported ($0.26) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.35) by $0.09. The company earned $45.51 million during the quarter, compared to the consensus estimate of $42.97 million. Cardlytics had a negative net margin of 11.08% and a negative return on equity of 19.42%. The company's revenue was up 26.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.23) EPS. View Cardlytics' earnings history.

6 equities research analysts have issued 12 month price objectives for Cardlytics' shares. Their forecasts range from $26.00 to $75.00. On average, they expect Cardlytics' stock price to reach $51.83 in the next twelve months. This suggests that the stock has a possible downside of 32.7%. View analysts' price targets for Cardlytics.

News articles about CDLX stock have been trending positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cardlytics earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news about Cardlytics.

Some companies that are related to Cardlytics include Legend Biotech (DADA), HUYA (HUYA), Switch (SWCH), DouYu International (DOYU), Medallia (MDLA), 21Vianet Group (VNET), SVMK (SVMK), Pluralsight (PS), Tripadvisor (TRIP), Sabre (SABR), Internet Initiative Japan (IIJIY), Model N (MODN), Health Catalyst (HCAT), Qutoutiao (QTT) and Eventbrite (EB). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardlytics investors own include Alibaba Group (BABA), Trade Desk (TTD), Advanced Micro Devices (AMD), NVIDIA (NVDA), Caterpillar (CAT), Roku (ROKU), Micron Technology (MU), Netflix (NFLX), Square (SQ) and Walt Disney (DIS).

(CDLX) raised $76 million in an IPO on Friday, February 9th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. BofA Merrill Lynch and J.P. Morgan acted as the underwriters for the IPO and Wells Fargo Securities, SunTrust Robinson Humphrey, Raymond James and KeyBanc Capital Markets were co-managers.

Cardlytics trades on the NASDAQ under the ticker symbol "CDLX."

Shares of CDLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CDLX stock can currently be purchased for approximately $77.01.

Cardlytics has a market capitalization of $2.08 billion and generates $210.43 million in revenue each year. The company earns $-17,140,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis.

The official website for Cardlytics is www.cardlytics.com.

Cardlytics' mailing address is 675 PONCE DE LEON AVENUE NE SUITE 6000, ATLANTA GA, 30308. The company can be reached via phone at 888-798-5802 or via email at [email protected]